<p>Discrepancies in results between cerebrospinal fluid (CSF) 14-3-3 protein and prion protein detection using real-time quaking-induced conversion (RT-QuIC) might limit the confidence in ante-mortem clinical diagnosis of sporadic Creutzfeldt–Jakob disease (sCJD). We aimed to evaluate the concordance and diagnostic performance of 14-3-3 protein and RT-QuIC in a real clinical practice cohort, and to analyze neuronal/glial damage biomarkers in sCJD patients based on their diagnostic assay results. A retrospective multicentre study was conducted on 157 suspected sCJD patients from 38 Spanish hospitals in a 4-year period. CSF 14-3-3 protein and RT-QuIC were simultaneously evaluated in a single laboratory. A diagnosis of probable sCJD was established in 63 patients (40.1%), of which 12 (19.0%) were ultimately diagnosed with definite sCJD. Forty-one sCJD patients (65.1%) were positive for both 14-3-3 protein and RT-QuIC, 17 (27.0%) isolated positive for RT-QuIC, and 5 (7.9%) isolated positive for 14-3-3 protein. RT-QuIC demonstrated higher sensitivity (92.1%) and specificity (98.9%) compared to 14-3-3 (73.0% and 62.8%) for the diagnosis of sCJD. Isolated RT-QuIC positivity was associated with longer disease duration (median: 10.5&#xa0;months, IQR: 8.8–15.7), higher frequency of Met/Val cases (75.0%), lower prevalence of periodic sharp-wave complexes (5.9%), and lower levels of GFAP (3967.4&#xa0;pg/mL), UCH-L1 (2218.1&#xa0;pg/mL), and t-Tau (228.8&#xa0;pg/mL) compared to double-positive and isolated 14-3-3-positive patients. In conclusion, CSF RT-QuIC is a highly specific and sensitive biomarker for ante-mortem sCJD diagnosis and should be considered as the preferred CSF ancillary test. Isolated RT-QuIC positivity indicates a less aggressive biological disease in sCJD patients.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Isolated CSF RT-QuIC positivity associates with a less aggressive disease course and decreased levels of neuronal/glial damage biomarkers in patients with sporadic Creutzfeldt–Jakob disease

  • Laura Naranjo,
  • Jordi Sarto,
  • Carlos Nos,
  • Daniel Alcolea,
  • Iñigo Rodríguez-Baz,
  • Irene Navalpotro-Gómez,
  • Aída Fernández-Lebrero,
  • Bernat Bertrán-Recasens,
  • María Elena Erro,
  • Ana Lara Pelayo-Negro,
  • Clara Esteve,
  • Susana Fernández,
  • Andreu Massot-Tarrús,
  • Anuncia Boltes,
  • Albert Torrents,
  • Nicolau Guanyabens,
  • Alfredo Palomino-García,
  • Natalia Egri,
  • Albert Lladó,
  • Mircea Balasa,
  • María Antonia Romera,
  • María del Carmen Antón,
  • Rocío Soledad Couso,
  • Raquel Sánchez-Valle,
  • Raquel Ruiz-García,
  • Mario Riverol,
  • Fermín Moreno-Izco,
  • Esther Catena,
  • Elisabet Franquet,
  • Vanesa A. Ortega,
  • M. Alba Mañé-Martínez,
  • Berta Alemany-Perna,
  • Alejandra Carvajal-Hernández,
  • María Elena Calzado-Rivas,
  • María Gómez-Eguílaz,
  • Elena Muñoz-Farjas,
  • Alba Velázquez,
  • Lorena García-Fernández,
  • Alejandro Herrero-San Martín,
  • Izaro Kortazar-Zubizarreta,
  • Alba Chavarría-Miranda,
  • Nikola Blažević,
  • María Eugenia López-Guio,
  • Soledad Sonsoles Muñoz,
  • Ana Isabel García-Sánchez,
  • María de Toledo-Heras,
  • Pablo Gómez-Porro,
  • Carlos Ordás-Bandera,
  • José Manuel Sánchez-Villalobos,
  • Ángel Pérez-Sempere,
  • María Balsalobre

摘要

Discrepancies in results between cerebrospinal fluid (CSF) 14-3-3 protein and prion protein detection using real-time quaking-induced conversion (RT-QuIC) might limit the confidence in ante-mortem clinical diagnosis of sporadic Creutzfeldt–Jakob disease (sCJD). We aimed to evaluate the concordance and diagnostic performance of 14-3-3 protein and RT-QuIC in a real clinical practice cohort, and to analyze neuronal/glial damage biomarkers in sCJD patients based on their diagnostic assay results. A retrospective multicentre study was conducted on 157 suspected sCJD patients from 38 Spanish hospitals in a 4-year period. CSF 14-3-3 protein and RT-QuIC were simultaneously evaluated in a single laboratory. A diagnosis of probable sCJD was established in 63 patients (40.1%), of which 12 (19.0%) were ultimately diagnosed with definite sCJD. Forty-one sCJD patients (65.1%) were positive for both 14-3-3 protein and RT-QuIC, 17 (27.0%) isolated positive for RT-QuIC, and 5 (7.9%) isolated positive for 14-3-3 protein. RT-QuIC demonstrated higher sensitivity (92.1%) and specificity (98.9%) compared to 14-3-3 (73.0% and 62.8%) for the diagnosis of sCJD. Isolated RT-QuIC positivity was associated with longer disease duration (median: 10.5 months, IQR: 8.8–15.7), higher frequency of Met/Val cases (75.0%), lower prevalence of periodic sharp-wave complexes (5.9%), and lower levels of GFAP (3967.4 pg/mL), UCH-L1 (2218.1 pg/mL), and t-Tau (228.8 pg/mL) compared to double-positive and isolated 14-3-3-positive patients. In conclusion, CSF RT-QuIC is a highly specific and sensitive biomarker for ante-mortem sCJD diagnosis and should be considered as the preferred CSF ancillary test. Isolated RT-QuIC positivity indicates a less aggressive biological disease in sCJD patients.